p53 expression in biopsies from children with Langerhans cell histiocytosis

Journal of Pediatric Hematology/Oncology

Volumn 24, Issue 9, 2002, Pages 733-736

  Bank, Micha I ^a   Rengtved, Pia ^a   Carstensen, Henrik ^a   Petersen, Bodil Laub ^a,b  

^a Mental Health Center Glostrup   (Denmark)

^b University of Copenhagen   (Denmark)

Author keywords

Apoptosis; Langerhans cell histiocytosis; p53

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; BIOPSY; BONE LESION; CLINICAL ARTICLE; CLINICAL EXAMINATION; CORRELATION ANALYSIS; DNA REPAIR; FEMALE; HISTIOCYTOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LANGERHANS CELL; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

BIOPSY; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GENES, P53; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036898531     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200212000-00010     Document Type: Article

References (20)

1. Lam K-Y. Langerhans cell histiocytosis (histiocytosis X). Posgrad Med J 1997;73:391-4.
2. Willman CL, Busque L, Griffith BB, et al. Langerhans'-cell histiocytosis (histiocytosis X): A clonal proliferative disease. N Engl J Med 1994;331:154-60.
3. Willman CL. Detection of clonal histiocytosis in Langerhans cell histiocytosis: Biology and clinical significance. Br J Cancer 1994;70 (suppl XXIII):29-33.
4. Yu RC, Chu C, Buluwelw L, et al. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet 1994;343:767-8.
5. Wu WS, McClain KL. DNA polymorphism and mutations of the tumor necrosis factor- (TNF-) promotor in Langerhans cell histiocytosis (LCH). J Interferon Cytokine Res 1997;17:631-5.
6. Writing Group of the Histiocyte Society. Histiocytosis syndromes in children. Lancet 1987;1:208-9.
7. Favara BE, Feller AC, Pauli M, et al. Contemporary classification of histiocyte disorders. Med Pediatr Oncol 1997;29:157-66.
8. Chu T, Jaffe R. The normal Langerhans cell and the LCH cell. Br J Cancer 1994;70(suppl XXIII):4-10.
9. Brodabent V, Gadner H. Current therapy for Langerhans cell histiocytosis. He. matol Oncol Clin North Am 1998;12:327-38.
10. Gadner H, Heitger A, Grois N, et al. Treatment strategy for disseminated Langerhans cell histiocytosis. Med Pediatr Oncol 1994;23:72-80.
11. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821-8.
12. Porter PL, Gown AM, Kramp SG, et al. Widespread p53 overexpression in human malignant tumors. Am J Pathol 1992;140:145-53.
13. Soussi T. p53 antibodies in the sera of patients with various types of cancer: A review. Cancer Res 2000;60:1777-88.
14. Weintraub M, Bhatia KG, Chandra RS, et al. p53 expression in Langerhans cell histiocytosis. J Pediatr Hematol Oncol 1998;20:12-7.
15. Takahashi M, Hidefumi T, Tada M, et al. Distinct prognostic values of p53 mutations and loss of estrogen receptor and their cumulative effect in primary breast cancers. Int J Cancer 2000;89:92-9.
16. Ko LJ, Prives C. p53: Puzzle and paradigm. Genes Dev 1996;10:1054-72.
17. Zhan Q, Carrier F, Fornace AJ. Induction of cellular p53 activity by DNA-damaging agents and growth arrest. Mol Cell Biol 1993;13:4242-50.
18. Graeber TG, Peterson JF, Tsai M, et al. Hypoxia induces accumulation of protein, but activation of a G1-phase checkpoint, by low-oxygen conditions is dependent of p53 status. Mot Cell Biol 1994;14:6264-77.
19. Momand J, Wu HH, Dasgupta G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000;242:15-29.
20. Donehower LA, Bradley A. The tumor suppressor p53. Biochim Biophys Acta 1993;1155:181-205.